Wednesday
January 17,2018

XTL BIOPHARMACEUTICL

http://www.xtlbio.com/





XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development:

The hCDR1 peptide is a novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (“SLE”). hCDR1 has completed three clinical trials involving more than 400 patients.
Recombinant Erythropoietin (rHuEPO) is a known compound we are developing for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival and improvement of their quality of life.



CEO

Joshua Levine

Phone:
972-9-955-7080

Email:
info@xtlbio.com


Profile: